The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

A particularly noteworthy achievement emerged this quarter: Eli Lilly's tirzepatide franchise overtook Merck's cancer immunotherapy Keytruda to become the world's highest-grossing medication. This ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Cipla has now entered into obesity Market with a partnership with Eli Lilly for Tirzepatide (GLP-1) is exclusive to the ...

The US Health Resources and Services Administration (HRSA) has approved nine drugs for a pilot testing a new rebate model ...

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...

After the Nasdaq sets a seven-year record, a slew of high flying stocks report in the coming week. Plus there's a bonus day from Tesla.

Argosy Investors reflects on Q3 moves, exiting Post Holdings and adding Endava and Novo Nordisk. Learn why overlooked sectors ...

Q3 2025 Earnings Call Transcript October 29, 2025 NiSource Inc. misses on earnings expectations. Reported EPS is $0.19 EPS, ...

GPU semiconductor factory, Jensen Huang’s roadmap connects data centers, networks, and industrial systems into a ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...